Ionis Pharmaceuticals Inc (IONS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Ionis Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 51.80 $ — 24% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 17.1% passed
- More than 10% revenue growth is expected for the coming year 67.9% passed
- Share count grows by less than 3% a year 4.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 0.0% failed
- Gross margin at 40% or higher and without meaningful erosion 98.3% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 63 m net cash passed
- Operating cash flow covers the profits of the last three years 124 m failed
- Return on capital at 15% or higher, or up versus two years ago -13.9% failed
- Insiders hold at least 10% or are net buyers 0.6% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 72.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 26
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.59 | -2.69 – -2.33 | 925 | -67.4% | 6 |
| 12/31/2027 | -1.44 | -2.47 – -0.12 | 1,406 | 44.1% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.66 | – | 227 | 89.60 | -46.10 | -116 | -142 |
| 2025: Q1 | -0.93 | – | 132 | 10.10 | -111.60 | -151 | -163 |
| 2025: Q2 | 0.68 | – | 452 | 100.70 | 27.30 | 151 | 137 |
| 2025: Q3 | -0.80 | – | 157 | 17.10 | -82.10 | -131 | -135 |
| 2025: Q4 | -1.41 | – | 203 | -10.40 | -112.80 | -138 | -159 |
| 2026: Q1 | -0.56 | – | 246 | 87.00 | -37.60 | -793 | -815 |
| 2026: Q2 | -0.69 | -201.50 | 268 | -40.70 | -42.80 | 566 | 549 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 347 | -46 | -87 | -0.72 | -112 | 100 | 912 |
| 2017 | 514 | 31 | 0 | 0.00 | 174 | 419 | 1,322 |
| 2018 | 600 | -61 | 274 | 2.04 | 603 | 1,187 | 2,668 |
| 2019 | 1,123 | 366 | 294 | 2.06 | 346 | 1,685 | 3,233 |
| 2020 | 729 | -172 | -487 | -3.49 | 36 | 843 | 2,390 |
| 2021 | 810 | -30 | -29 | -0.20 | 31 | 772 | 2,612 |
| 2022 | 587 | -410 | -270 | -1.90 | -274 | 573 | 2,534 |
| 2023 | 788 | -354 | -366 | -2.56 | -308 | 387 | 2,990 |
| 2024 | 705 | -475 | -454 | -3.04 | -501 | 588 | 3,004 |
| 2025 | 944 | -382 | -381 | -2.38 | -269 | 489 | 3,524 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Ionis Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen in der kommerziellen Phase, das RNA-zielgerichtete Medikamente in den USA anbietet.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 1,480 |
| Headquarters | Carlsbad, CA |
| Address | 2855 Gazelle Court, 92010 Carlsbad, United States |
| Phone | 760 931 9200 |
| Website | ionis.com |
| IPO Date | 17. May 1991 |
| ISIN | US4622221004 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Brett P. Monia Ph.D. | Founder, CEO & Director | 1961 |
| Patrick R. O'Neil Esq. | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | 1974 |
| Brian Birchler | Executive Vice President of Corporate & Development Operations | 1966 |
| Richard S. Geary Ph.D. | Strategic Consultant | 1958 |
| Eugene Schneider M.D. | Executive VP, Chief Clinical Development & Operations Officer | 1973 |
| Darren Gonzales | Chief Accounting Officer & Senior VP | – |
| C. Frank Bennett BSc, Ph.D. | Executive VP & Chief Scientific Officer | 1957 |
| D. Wade Walke Ph.D. | Senior Vice President of Investor Relations | – |
| Tracy Berns J.D. | Senior VP and Chief Compliance & Quality Assurance Officer | – |
| Hayley Soffer | Vice President of Corporate Communications | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 31. Jul 2026 | Hayden Michael R | Director | Buy | 5,000 | 51.60 | 258,000 |
| 30. Jul 2026 | Hayden Michael R | Director | Buy | 15,000 | 53.38 | 800,700 |
| 15. Jul 2026 | Herman Joan E | Director | Other | 5,220 | 0.00 | – |
| 15. Jul 2026 | Berthelsen Spencer R | Director | Other | 5,220 | 0.00 | – |
| 7. Jul 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Sell | 15,000 | 85.46 | 1,281,930 |
| 7. Jul 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Other | 15,000 | 0.00 | – |
| 7. Jul 2026 | Bennett C Frank | EVP, Chief Scientific Officer | Sell | 5,536 | 83.58 | 462,693 |
| 7. Jul 2026 | Diaz Allene M. | Director | Sell | 10,111 | 85.42 | 863,637 |
| 7. Jul 2026 | Diaz Allene M. | Director | Other | 10,111 | 47.11 | 476,329 |
| 7. Jul 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | Sell | 362 | 84.30 | 30,517 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.